A Phase IIa Study in Primary IgA Nephropathy Patients

Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

NCT05510323 ·Status: RECRUITING ·Phase: PHASE3

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576 ·Status: RECRUITING ·Phase: PHASE2

Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

NCT07476872 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

NCT03616184 ·Status: COMPLETED ·Phase: PHASE2

A Study With Imlifidase in Anti-GBM Disease

NCT05679401 ·Status: TERMINATED ·Phase: PHASE3

Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis

NCT07595367 ·Status: RECRUITING ·Phase: PHASE2

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

NCT00464321 ·Status: COMPLETED ·Phase: PHASE1

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

NCT00076726 ·Status: TERMINATED ·Phase: PHASE2

Complement C5 mAb in the Treatment of Anti-GBM Disease

NCT06513338 ·Status: COMPLETED ·Phase: PHASE2

Pilot Study of Velcade® in IgA Nephropathy

NCT01103778 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome

NCT03560011 ·Status: SUSPENDED ·Phase: PHASE2/PHASE3

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

NCT04779957 ·Status: COMPLETED ·Phase: PHASE2

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

NCT03492710 ·Status: WITHDRAWN ·Phase: PHASE3

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation

NCT07381114 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

NCT00490100 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

NCT06858319 ·Status: RECRUITING ·Phase: PHASE3

Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy

NCT02647255 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Anti-Cytokine Therapy for Vasculitis

NCT00753103 ·Status: COMPLETED ·Phase: PHASE2

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563 ·Status: RECRUITING ·Phase: PHASE3

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

NCT04614558 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout

NCT01466166 ·Status: COMPLETED

Telitacicept for PGNMID: A Single-Arm Study

NCT07111338 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

NCT01573533 ·Status: COMPLETED ·Phase: PHASE2

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

NCT03217617 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078 ·Status: RECRUITING ·Phase: PHASE2